Levosimendan meta-analyses: Is there a pattern in the effect on mortality?

International Journal of Cardiology

Volumn 209, Issue , 2016, Pages 77-83

  Pollesello, P ^a   Parissis, J ^b   Kivikko, M ^a   Harjola, V P ^c  

^a ORION CORPORATION   (Finland)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Acute cardiac care; Cardiac surgery; Heart failure; Inodilator; Meta analysis; Mortality

Indexed keywords

LEVOSIMENDAN; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ACUTE HEART FAILURE; CARDIOVASCULAR MORTALITY; DATA ANALYSIS; DRUG EFFECT; DRUG RESPONSE; DRUG USE; HEART FAILURE; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SEPSIS; CAUSE OF DEATH; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; HEART DISEASES; META ANALYSIS (TOPIC); MORTALITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

CARDIOTONIC AGENTS; CAUSE OF DEATH; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; HEART DISEASES; HUMANS; HYDRAZONES; META-ANALYSIS AS TOPIC; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84961727444     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.02.014     Document Type: Review

References (46)

1. Z. Papp, I. Édes, S. Fruhwald, S.G. De Hert, M. Salmenperä, H. Leppikangas, and et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan Int. J. Cardiol. 159 2 2012 82 87
2. M.S. Nieminen, S. Fruhwald, L.M. Heunks, P.K. Suominen, A.C. Gordon, M. Kivikko, and et al. Levosimendan: current data, clinical use and future development Heart Lung Vessel. 5 4 2013 227 245
3. T. Greco, A. Zangrillo, G. Biondi-Zoccai, and G. Landoni Meta-analysis: pitfalls and hints Heart Lung Vessel. 5 4 2013 219 225
4. J.G. Cleland, J. Ghosh, N. Freemantle, G.C. Kaye, M. Nasir, A.L. Clark, and et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure Eur. J. Heart Fail. 6 4 2004 501 508
5. J.G. Cleland, N. Freemantle, A.P. Coletta, and A.L. Clark Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE Eur. J. Heart Fail. 8 1 2006 105 110
6. A. Zangrillo, G. Biondi-Zoccai, A. Mizzi, G. Bruno, E. Bignami, C. Gerli, and et al. Levosimendan reduces cardiac troponin release after cardiac surgery: a meta-analysis of randomized controlled studies J. Cardiothorac. Vasc. Anesth. 23 4 2009 474 478
7. G. Landoni, A. Mizzi, G. Biondi-Zoccai, E. Bignami, P. Prati, V. Ajello, and et al. Levosimendan reduces mortality in critically ill patients. A meta-analysis of randomized controlled studies Minerva Anestesiol. 76 4 2010 276 286
8. R.A. Ribeiro, L.E. Rohde, and C.A. Polanczyk Levosimendan in acute decompensated heart failure: systematic review and meta-analysis Arq. Bras. Cardiol. 95 2 2010 230 237
9. G. Landoni, A. Mizzi, G. Biondi-Zoccai, G. Bruno, E. Bignami, L. Corno, and et al. Reducing mortality in cardiac surgery with levosimendan: a meta-analysis of randomized controlled trials J. Cardiothorac. Vasc. Anesth. 24 1 2010 51 57
10. A. Delaney, C. Bradford, J. McCaffrey, S.M. Bagshaw, and R. Lee Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials Int. J. Cardiol. 138 3 2010 281 289
11. R. Maharaj, and V. Metaxa Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials Crit. Care 15 3 2011 R140
12. G. Landoni, G. Biondi-Zoccai, M. Greco, T. Greco, E. Bignami, A. Morelli, and et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies Crit. Care Med. 40 2012 634 646
13. A. Hernández, A. Miranda, and A. Parada Levosimendan reduces mortality in cardiac surgery: a systematic review and meta-analysis Rev. Esp. Anestesiol. Reanim. 59 1 2012 6 11
14. X. Huang, S. Lei, M.F. Zhu, R.L. Jiang, L.Q. Huang, G.L. Xia, and et al. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials J. Zhejiang Univ. Sci. B 14 5 2013 400 415
15. R.W. Harrison, V. Hasselblad, R.H. Mehta, R. Levin, R.A. Harrington, and J.H. Alexander Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis J. Cardiothorac. Vasc. Anesth. 27 6 2013 1224 1232
16. Z.Z. Niu, S.M. Wu, W.Y. Sun, W.M. Hou, and Y.F. Chi Perioperative levosimendan therapy is associated with a lower incidence of acute kidney injury after cardiac surgery: a meta-analysis J. Cardiovasc. Pharmacol. 63 2 2014 107 112
17. Nieminen MS, J. Altenberger, T. Ben-Gal, A. Böhmer, J. Comin-Colet, K. Dickstein, and et al. Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus Int. J. Cardiol. 174 2 2014 360 367
18. S. Silvetti, T. Greco, A.L. Di Prima, M. Mucchetti, C.M. de Lurdes, L. Pasin, and et al. Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials Clin. Res. Cardiol. 103 7 2014 505 513
19. G. Koster, J. Wetterslev, C. Gluud, J.G. Zijlstra, T.W. Scheeren, I.C. van der Horst, and et al. Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis Intensive Care Med. 41 2 2015 203 221
20. T. Bove, A. Matteazzi, A. Belletti, G. Paternoster, O. Saleh, D. Taddeo, and et al. Beneficial impact of levosimendan in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials Heart Lung Vessel. 7 1 2015 35 46
21. T. Greco, M.G. Calabrò, R.D. Covello, M. Greco, L. Pasin, A. Morelli, and et al. A Bayesian network meta-analysis on the effect of inodilatory agents on mortality Br. J. Anaesth. 114 5 2015 746 756
22. G.Y. Yi, J.X. Li, J. Zhang, L.L. Niu, and C.Y. Zhang Repetitive infusion of levosimendan in patients with chronic heart failure: a meta-analysis Med. Sci. Monit. 21 2015 895 901
23. J.Y. Lim, S.V. Deo, A. Rababa'h, S.E. Altarabsheh, Y.H. Cho, D. Hang, and et al. Levosimendan reduces mortality in adults with left ventricular dysfunction undergoing cardiac surgery: a systematic review and meta-analysis J. Card. Surg. 30 7 2015 547 554
24. B. Gong, Z. Li, and P.C. Yat Wong Levosimendan treatment for heart failure: a systematic review and meta-analysis J. Cardiothorac. Vasc. Anesth. 29 2015 1415 1425
25. A. Zangrillo, A. Putzu, F. Monaco, A. Oriani, G. Frau, M. De Luca, and et al. Levosimendan reduces mortality in patients with severe sepsis and septic shock: a meta-analysis of randomized trials J. Crit. Care 2015 10.1016/j.jcrc.2015.05.017
26. S. Silvetti, and M.S. Nieminen Repeated or intermittent levosimendan treatment in advanced heart failure: an updated meta-analysis Int. J. Cardiol. 202 2016 138 143
27. A. Belletti, M.L. Castro, S. Silvetti, T. Greco, G. Biondi-Zoccai, L. Pasin, and et al. The effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials Br. J. Anaesth. 115 5 2015 656 675
28. C. Zhou, J. Gong, D. Chen, W. Wang, M. Liu, and B. Liu Levosimendan for prevention of acute kidney injury after cardiac surgery: a meta-analysis of randomized controlled trials Am. J. Kidney Dis. 2015 Oct 27 10.1053/j.ajkd.2015.09.015
29. M.T. Slawsky, W.S. Colucci, S.S. Gottlieb, B.H. Greenberg, E. Haeusslein, J. Hare, and et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure Circulation 102 18 2000 2222 2227
30. M.S. Nieminen, J. Akkila, G. Hasenfuss, F.X. Kleber, L.A. Lehtonen, V. Mitrovic, and et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure J. Am. Coll. Cardiol. 36 6 2000 1903 1912
31. F. Follath, J.G. Cleland, H. Just, J.G. Papp, H. Scholz, K. Peuhkurinen, and et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial Lancet 360 9328 2002 196 202
32. V.S. Moiseyev, P. Põder, N. Andrejevs, M.Y. Ruda, A.P. Golikov, L.B. Lazebnik, and et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN) Eur. Heart J. 23 18 2002 Sep 1422 1432
33. A. Mebazaa, M.S. Nieminen, M. Packer, A. Cohen-Solal, F.X. Kleber, S.J. Pocock, and et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial JAMA 297 17 2007 May 2 1883 1891
34. M. Packer, W. Colucci, L. Fisher, B.M. Massie, J.R. Teerlink, J. Young, and et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure JACC Heart Fail. 1 2 2013 Apr 103 111
35. Review manager (RevMan) [Computer program] version 5.0. Copenhagen The Nordic Cochrane Centre, the Cochrane Collaboration 2008 ([Available at: http://ims.cochrane.org/revman. Accessed 10 September, 2015])
36. L. De Luca Inotropic agents in advanced heart failure: repetita iuvant? Int. J. Cardiol. 176 1 2014 6 7
37. M. Kivikko, M.S. Nieminen, P. Pollesello, P. Pohjanjousi, W.S. Colucci, J.R. Teerlink, and et al. The clinical effects of levosimendan are not attenuated by sulfonylureas Scand. Cardiovasc. J. 46 6 2012 330 338
38. L. Qiao, C. Xu, X. Li, F. Li, and W. Liu Heart calcium sensitizer on morbidity and mortality of high-risk surgical patients with MODS: systematic review and meta-analysis Int. J. Clin. Exp. Med. 8 10 2015 17712 17720
39. J.P.T. Higgins, and S. Green Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0, Updated March 2011 http://www.cochranehandbook.org (4 January 2011)
40. C.B. Begg, and M. Mazumdar Operating characteristics of a rank correlation test for publication bias Biometrics 50 1994 1088 1101
41. M. Egger, G. Davey Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
42. W. Toller, M. Heringlake, F. Guarracino, L. Algotsson, J. Alvarez, H. Argyriadou, and et al. Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion Int. J. Cardiol. 184 2015 323 336
43. R.M. Orme, G.D. Perkins, D.F. McAuley, K.D. Liu, A.J. Mason, A. Morelli, and et al. An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial Trials 15 2014 199
44. P. Pollesello, Z. Papp, and JGy Papp Calcium sensitizers:what have we learned over the last 25 years? Int. J. Cardiol. 203 2016 543 548
45. C.L. Tacon, J. McCaffrey, and A. Delaney Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials Intensive Care Med. 38 2012 359 367
46. P. Nony, J.P. Boissel, M. Lievre, A. Leizorovicz, M.C. Haugh, S. Fareh, and et al. Evaluation of the effect of phosphodiestherase inhibitors on mortality in chronic heart failure patients. A meta-analysis Eur. J. Clin. Pharmacol. 46 1994 191 196